Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $16 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and RVTY perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. RVTY has a comprehensive life sciences and diagnostics portfolio, including reagents, assay kits and imaging solutions for drug discovery to diagnostics. Innovation in HTRF, LANCE Ultra and DELFIA has positioned it as a leader in multi-omics and biomarker identification. With presence in 160+ countries and about 2,000 sales reps, its global reach ensures diversified revenues and mitigates regional risks while driving superior quality and customer experience.